Balyasny Asset Management L.P. Makes New Investment in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Balyasny Asset Management L.P. purchased a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 17,153 shares of the company’s stock, valued at approximately $58,000.

Other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. increased its position in Xeris Biopharma by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company’s stock valued at $26,778,000 after purchasing an additional 133,738 shares during the period. Geode Capital Management LLC grew its holdings in Xeris Biopharma by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 3,351,426 shares of the company’s stock worth $11,364,000 after acquiring an additional 17,956 shares during the period. AIGH Capital Management LLC grew its holdings in Xeris Biopharma by 17.8% during the 4th quarter. AIGH Capital Management LLC now owns 2,574,846 shares of the company’s stock worth $8,729,000 after acquiring an additional 389,192 shares during the period. Renaissance Technologies LLC boosted its position in shares of Xeris Biopharma by 31.3% during the 4th quarter. Renaissance Technologies LLC now owns 2,098,840 shares of the company’s stock valued at $7,115,000 after purchasing an additional 500,120 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Xeris Biopharma by 3.3% during the 4th quarter. Northern Trust Corp now owns 1,196,381 shares of the company’s stock worth $4,056,000 after buying an additional 38,155 shares in the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Insiders Place Their Bets

In other Xeris Biopharma news, insider Beth Hecht sold 40,000 shares of the business’s stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the sale, the insider now directly owns 1,353,510 shares in the company, valued at $7,349,559.30. The trade was a 2.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 6.47% of the company’s stock.

Xeris Biopharma Trading Down 0.2%

Shares of Xeris Biopharma stock opened at $4.87 on Tuesday. The business’s fifty day simple moving average is $4.73 and its 200 day simple moving average is $3.93. Xeris Biopharma Holdings, Inc. has a 12 month low of $1.86 and a 12 month high of $6.07. The firm has a market capitalization of $761.59 million, a P/E ratio of -10.82 and a beta of 1.10.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. The business had revenue of $57.80 million for the quarter, compared to the consensus estimate of $57.61 million. Analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Craig Hallum boosted their target price on shares of Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a research report on Friday, March 7th. Oppenheimer upped their price target on Xeris Biopharma from $6.00 to $7.00 and gave the stock an “outperform” rating in a research note on Friday, May 9th. Piper Sandler reissued a “neutral” rating and issued a $4.00 price target (up previously from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Leerink Partners boosted their price objective on Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a report on Friday, March 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 target price (up previously from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $6.25.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.